Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Status:
Unknown status
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This phase III trial is aimed to investigate the efficacy of an individualized,
sensitivity-directed combination chemotherapy in comparison to the standard regimen DTIC.
Two question are aimed to be answered by this study:
1. Is the individual chemosensitivity index (BICSI) a prognostic / predictive biomarker for
chemotherapy ?
2. Is an individualized, sensitivity-directed combination chemotherapy superior to the
standard regimen DTIC in terms of survival and response ?
Phase:
Phase 3
Details
Lead Sponsor:
University of Wuerzburg
Collaborators:
DCS Innovative Diagnostik Systeme Hiege-Stiftung gegen Hautkrebs medac GmbH